Cytokine release syndrome occurred in 70% of patients, with lower incidence in those pre-treated with 2,000 mg Gazyva. Severe ...
Hosted on MSN1mon
Roche's Lupus Study for Gazyva Meets Primary & Key Secondary GoalsRHHBY’s Plans Forward for Gazyva/Gazyvaro to Treat Lupus Roche is currently gearing up to discuss the late-stage REGENCY study data with regulatory authorities in the United States and EU. LN is ...
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) unit Genentech announced Thursday that Gazyva, a lymphoma therapy it co-develops with ...
Roche has presented new data which shows Gazyva is superior to its established Rixtuxan/Mabthera in treating follicular lymphoma (FL). Rituxan/MabThera is one of Roche's biggest sellers ...
Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic ...
Roche announced positive topline results from the phase III REGENCY study of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis. In the study, a higher proportion of people treated ...
Roche’s recent Phase III REGENCY trial results for Gazyva (obinutuzumab) suggest the therapy could directly address these needs. Gazyva, a CD20-directed cytolytic antibody, met its primary endpoint by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback